Glargine U300 Hospital Trial
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 247 participants.
Also called NCT03013985
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 247 participants
- Sponsor
- Registry
-
NCT03013985
-
- Other papers using this trial's data
- A Randomized Controlled Trial Comparing Glargine U300 and Glargine U100 for the Inpatient Management of Medicine and Surgery Patients With Type 2 Diabetes: Glargine U300 Hospital Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03013985. Randomized; no masking; primary purpose treatment. Start 2017-05-17 (actual); primary completion 2019-03-22 (actual). Results posted on 2020-05-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Glargine U300 Hospital Trial
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Glargine U300
- Intervention (Drug)
- Glargine U100
- Intervention (Drug)
- Glulisine Insulin
- Lead sponsor
- Emory University
Record details
- Record id
cardio:ct-nct03013985- Content hash
958bcf0fda4594807a72d46138cb2e74a18e76af83ee6ad6382a5bafe4c61a3e